NASDAQ:PBYI - Puma Biotechnology Stock Price, Price Target & More

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

Puma Biotechnology (NASDAQ:PBYI) issued its quarterly earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.65) EPS for the quarter, topping the Zacks' consensus estimate of ($1.26) by $0.61. The biopharmaceutical company earned $66.50 million during the quarter, compared to the consensus estimate of $67.33 million. During the same quarter in the previous year, the business posted ($1.16) EPS. View Puma Biotechnology's Earnings History.

Puma Biotechnology is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Puma Biotechnology.

9 equities research analysts have issued 12 month price objectives for Puma Biotechnology's stock. Their predictions range from $68.00 to $146.00. On average, they anticipate Puma Biotechnology's share price to reach $102.2222 in the next twelve months. View Analyst Ratings for Puma Biotechnology.

Some companies that are related to Puma Biotechnology include Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Catalent (CTLT), GALAPAGOS NV/S (GLPG), Agios Pharmaceuticals (AGIO), Loxo Oncology (LOXO), Dr. Reddy's Laboratories (RDY), Taro Pharmaceutical Industries (TARO), United Therapeutics (UTHR), GW Pharmaceuticals (GWPH), FibroGen (FGEN) and Hutchison China MediTech (HCM).

Media headlines about PBYI stock have been trending somewhat positive recently, according to Accern. The research group scores the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Puma Biotechnology earned a coverage optimism score of 0.10 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 46.82 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Puma Biotechnology's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.28%), Point72 Asset Management L.P. (3.39%), Redmile Group LLC (2.90%), Franklin Resources Inc. (2.27%), venBio Select Advisor LLC (2.18%) and Rock Springs Capital Management LP (1.09%). Company insiders that own Puma Biotechnology stock include Adage Capital Partners Gp, LL, Alan H Auerbach, Charles R Eyler, Richard Paul Bryce and Robert Charnas. View Institutional Ownership Trends for Puma Biotechnology.

PBYI stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, UBS Group AG, Millennium Management LLC, Eversept Partners LLC, BlackRock Inc., Sivik Global Healthcare LLC, California Public Employees Retirement System and Teacher Retirement System of Texas. Company insiders that have sold Puma Biotechnology company stock in the last year include Adage Capital Partners Gp, LL, Alan H Auerbach, Charles R Eyler and Richard Paul Bryce. View Insider Buying and Selling for Puma Biotechnology.

PBYI stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., venBio Select Advisor LLC, Summit Trail Advisors LLC, Redmile Group LLC, BNP Paribas Arbitrage SA, PointState Capital LP, Federated Investors Inc. PA and Rock Springs Capital Management LP. View Insider Buying and Selling for Puma Biotechnology.

Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PBYI stock can currently be purchased for approximately $51.90.

Puma Biotechnology has a market capitalization of $1.95 billion and generates $26.20 million in revenue each year. The biopharmaceutical company earns $-291,950,000.00 in net income (profit) each year or ($7.85) on an earnings per share basis. Puma Biotechnology employs 318 workers across the globe.

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected]